ClinicalTrials.Veeva

Menu
A

ASST Grande Ospedale Metropolitano Niguarda | Ematologia Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ibrutinib
Olezarsen
Pembrolizumab
Dexamethasone
Empagliflozin
Lenalidomide
Venetoclax
RO7204239
Cisplatin
Risankizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

58 of 157 total trials

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Enrolling
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Active, not recruiting
Type 2 Diabetes
Drug: IcoSema
Drug: Insulin glargine

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Active, not recruiting
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants wi...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Tocilizumab
Drug: Venetoclax

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Drug: Capmatinib

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombin...

Enrolling
Carcinoma, Non-small-Cell Lung
Drug: Lazertinib
Drug: Direct Oral Anticoagulant (DOAC)

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...

Enrolling
Leukemia, Myeloid, Acute
Drug: Cytarabine
Drug: Bleximenib

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as mon...

Active, not recruiting
Metastatic Colorectal Cancer
Drug: Balstilimab
Drug: Standard of Care

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic c...

Active, not recruiting
Colorectal Cancer
Drug: regorafenib
Biological: favezelimab/pembrolizumab

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Drug: Cetrelimab

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cusatuzumab
Drug: Azacitidine

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with...

Active, not recruiting
Advanced Solid Tumor
Drug: Erdafitinib

The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for...

Active, not recruiting
Urothelial Carcinoma
Drug: Cisplatin
Drug: Erdafitinib

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with rel...

Active, not recruiting
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: JNJ-67856633

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting
Prostatic Neoplasms, Castration-Resistant
Drug: Niraparib 200 mg
Drug: Cetrelimab 480 mg

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Prednisone
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Boehringer Ingelheim logo
AbbVie logo
N
Roche logo
Bayer logo
Daiichi Sankyo logo
Merck Sharp & Dohme (MSD) logo
Ionis Pharmaceuticals logo
Novo Nordisk logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems